Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics

BridgeBio Pharma +0.65%
Invitae Corp. 0.00%

BridgeBio Pharma






 Invitae (NYSE:NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, designed to advance genetics-based drug discovery for rare diseases. The goal of the collaboration is to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs. 

Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via